AxoGen, Inc. to Report Fourth Quarter and Full Year 2013 Financial Results on March 6, 2014

Alachua, FL (PRWEB) February 12, 2014

AxoGen, Inc. (NASDAQ: AXGN), the only company completely focused on peripheral nerve repair, will report results for the fourth quarter and full year ended December 31, 2013 on Thursday, March 6, 2014 after the market closes.

The Company will host a conference call and webcast for the investment community on Thursday, March 6, 2014 at 4:30 PM ET. Investors within the United States interested in participating are invited to call 877-674-2413 and reference the Participant Passcode 94925592. All other participants can use the dial-in number 1-914-495-8604, using the same Participant Passcode. To access the webcast, please visit http://www.AxoGenInc.com/Investors/html. Following the conference call, a replay will be available on the Company's website at http://www.AxoGenInc.com, under ‘Investors.'

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a medical products company based in Alachua, Florida. Founded in 2002, AxoGen is the only company to focus entirely on peripheral nerve repair. AxoGen's portfolio of products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen. AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.

Source: AxoGen, Inc.

Released February 12, 2014